Skinport is a medical technology start-up formed in Latvia in 2021 with a support of Comercialisation Reactor Latvia. SkinPort has developed microneedle arrays required for reliable insertion into flexible skin and to deliver already approved vaccines and drugs. The patented painless SkinPort microneedle array is a unique and superior technology allowing effective delivery of all vaccines, including particle-based and DNA vaccines, liquid drugs, or injectable cosmetics with up to 1 MDa molecular mass uniformly into a set area of the skin and to a depth of 300microns. SkinPort microneedle arrays can be inexpensively manufactured using mature high-volume, low-cost processes.
